X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Assertio will expand its product portfolio by including Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation for the treatment of febrile neutropenia.
Lead Product(s): Eflapegrastim-xnst
Therapeutic Area: Infections and Infectious Diseases Product Name: Rolvedon
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Assertio Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 31, 2023
Details:
Through the acquisition, Assertio will expand its product portfolio by including Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation for the treatment of febrile neutropenia.
Lead Product(s): Eflapegrastim-xnst
Therapeutic Area: Hematology Product Name: Rolvedon
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Assertio Therapeutics
Deal Size: $757.0 million Upfront Cash: $291.0 million
Deal Type: Acquisition April 25, 2023
Details:
ROLVEDON™ (eflapegrastim-xnst) injection is a long-acting G-CSF which decreases the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.
Lead Product(s): Eflapegrastim
Therapeutic Area: Hematology Product Name: Rolvedon
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
HM781-36B (poziotinib) is a novel, oral EGFR TKI that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4, which, in turn, leads to the inhibition of the proliferation of tumor cells that overexpress these receptors.
Lead Product(s): Poziotinib
Therapeutic Area: Oncology Product Name: HM781-36B
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022
Details:
HM781-36B (poziotinib) is a novel, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4.
Lead Product(s): Poziotinib
Therapeutic Area: Oncology Product Name: HM781-36B
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
ROLVEDON™ (eflapegrastim-xnst) injection is a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation,is indicated to decrease the incidence of infection, as manifested by febrile neutropenia.
Lead Product(s): Eflapegrastim
Therapeutic Area: Hematology Product Name: Rolvedon
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
HM781-36B (poziotinib) is a novel, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4.
Lead Product(s): Poziotinib
Therapeutic Area: Oncology Product Name: HM781-36B
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
HM781-36B (Poziotinib), novel, oral epidermal growth factor receptor tyrosine kinase inhibitor that inhibits tyrosine kinase activity of EGFR, HER2 and HER4. Importantly this, in turn, leads to inhibition of proliferation of tumor cells that overexpress these receptors.
Lead Product(s): Poziotinib
Therapeutic Area: Oncology Product Name: HM781-36B
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
In pre-clinical models of cancer, poziotinib, an investigational, orally administered, irreversible tyrosine kinase inhibitor was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death.
Lead Product(s): Poziotinib
Therapeutic Area: Oncology Product Name: HM781-36B
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
ZENITH 20 study demonstrated positive results for Poziotinib, met its primary endpoint as the observed lower bound of 30% exceeded the pre-specified lower bound of 20%, showed a confirmed objective response rate of 41% in patients with non-small lung cancer.
Lead Product(s): Poziotinib
Therapeutic Area: Oncology Product Name: HM781-36B
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
